Principal Investigator

Sylvie Mader

Molecular Targeting in Breast Cancer Treatment

Subscribe to the newsletter

After training at the PaAfter studying at the École Normale Supérieure in Paris, the University of Paris VI, and the Pasteur Institute, Sylvie Mader joined Pierre Chambon’s team at the University of Louis Pasteur in Strasbourg to pursue a Ph.D. in biochemistry, which she completed in 1991. Her work contributed to a better understanding of how nuclear receptors bind to DNA to regulate the transcription of their target genes.

She then joined Nahum Sonenberg’s team at McGill University for a postdoctoral fellowship, where she identified a mechanism of translation control involving competition among several proteins for interaction with the translation initiation factor eIF4E.

She then joined the Department of Biochemistry at the University of Montreal in 1995 and was recruited by IRIC in 2005.
ris École normale supérieure, the Université de Paris VI and at the Institut Pasteur, Sylvie Mader joined Pierre Chambon’s team at the Louis Pasteur Université in Strasbourg for a Ph.D. in Biochemistry, which she completed in 1991.

The Investigator then joined Nahum Sonenberg’s team, at McGill University, for postdoctoral training where she brought to light a control mechanism of translation involving eIF4E. She joined the Université de Montréal in 1995 and was recruited by the IRIC in 2005.

Principal Investigator, Molecular Targeting in Breast Cancer Treatment Research Unit, IRIC
Chemogenix Core Facility Scientific Co-Director

Professor, Department of Biochemistry and Molecular Medicine, Faculty of Medicine, Université de Montréal

Research unit on molecular targeting in breast cancer

Marcelle-Coutu Pavilion, 3306-7

Phone (office)
(514) 343-7166
Fax
(514) 343-7780
Email
sylvie.mader@umontreal.ca

Molecular Targeting in Breast Cancer Treatment

Sylvie Mader and her team try to identify the causes of the diversity of mammary tumors and how they impact the response to the drugs used in breast cancer treatment. The group strives to better understand the response or resistance mechanisms to the drugs used in breast cancer treatment and to identify new therapeutic targets to optimize its treatment.

Research topics

Publications